OpenOnco
UA EN

Onco Wiki / Biomarker

Germline BRCA1/2 mutation status

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBIO-BRCA-GERMLINE
TypeBiomarker
Aliases
Гермінальний статус мутацій BRCA1/2
Statuspending_clinical_signoff
DiseasesNone declared
SourcesNone declared

Biomarker Facts

Biomarker typegene_mutation
Mutation details{"functional_impact": "loss-of-function (HRR pathway)", "gene": "BRCA1, BRCA2", "inheritance": "germline", "type": "various pathogenic / likely-pathogenic variants"}
Measurement
MethodNGS panel (germline) with Sanger confirmation of variants of interest
Sensitivity requirementPathogenic variants captured per ACMG variant-classification standards
Related biomarkersBIO-HRR-PANEL

Notes

Germline testing should be offered to all metastatic prostate patients per NCCN 2025 (regardless of family history). Cascade testing important for relatives. Germline + tumor (somatic) testing complementary.

Used By

Biomarker

Indications

Questionnaires

Red flag

Tests